Journal of Hepatology: New Discovery! Weekend Sleep Can Relieve Non-Alcoholic Fatty Liver

Sleep time is an important indicator to measure the health of the human body, and the liver is necessary to maintain life and plays an important role in metabolism
.

Non-alcoholic Fatty Liver Disease (NAFLD) is a metabolic liver disease caused by excessive fat accumulation, with a high incidence worldwide

Previous studies have found that insufficient sleep is inversely associated with liver fibrosis, and insufficient sleep and poor sleep quality can trigger multiple pathophysiological processes associated with NAFLD
.

Recently, a study titled " Weekend catch-up sleep is associated with the alleviation of non-alcoholic fatty liver disease " published in the journal Hepatology showed that weekend sleep supplementation can alleviate non-alcoholic fatty liver disease ( Figure 1 )

Weekend catch-up sleep is associated with the alleviation of non-alcoholic fatty liver disease Weekend catch-up sleep is associated with the alleviation of non-alcoholic fatty liver diseaseFigure 1

Figure 1 Research results (source: [1])

Figure 1 Research results (source: [1]) Figure 1 Research results (source: [1])

This study recorded data on sleep duration from the Korea National Health and Nutrition Examination Survey (KNHANES) from 2008 to 2019
.

Due to the different sleep durations collected by KNHANES in 2016, the total data were divided into set 1 (n=26988) and set 2 (n=11714) according to the type of sleep duration collected

The hepatic steatosis index (HSI) was used in this study to determine the presence of fatty liver
.

The calculation formula of HSI is: HSI=8×(ALT/AST)+BMI (women+2, diabetes+2), HSI≥36 is considered as an indicator of fatty liver (ALT: alanine aminotransferase, alanine aminotransferase; AST: aspartate aminotransferase, aspartate aminotransferase, aspartate aminotransferase, aspartate aminotransferase, aspartate aminotransferase, aspartate aminotransferase, aspartate aminotransferase.

Table 1 Association of sleep duration and quality with NAFLD risk in clinically relevant subgroups

Table 1 Association of sleep duration and quality with NAFLD risk in clinically relevant subgroupsTable 1 Association of sleep duration and quality with NAFLD risk in clinically relevant subgroups

Table source: [1]

Source of table: [1] Source of table: [1]

In KNHANES dataset 2, 2365 (20.
2%), 2602 (22.
2%), and 6747 (57.
6%) subjects were included in groups 1, 2, and 3, respectively
.

Based on group 1, the risk of NAFLD was reduced in both groups 2 and 3; when subjects were divided into male and female groups for comparative analysis, it was found that the risk of NAFLD was also reduced in groups 2 and 3

Advances in the treatment of NAFLD in my country

The treatment progress of NAFLD in China The treatment progress of NAFLD in China

In recent years, fatty liver disease has replaced chronic hepatitis B as the most common chronic liver disease in China
.

The number of NAFLD patients in China is increasing rapidly, and the age of onset tends to be younger, which has gradually become an important public health problem.

1.
Life behavior correction

1.
Life behavior correction

It is now generally accepted that weight loss is the strongest factor associated with improved liver histology in patients with non-alcoholic steatohepatitis (NASH), and modification of activities of daily living, including a healthy diet (rejection of high calorie, high fat and High-sugar diet), alcohol rejection, and increased physical activity have become first-line treatment strategies for NAFLD and NASH
.

2.
Drug treatment

2.
Drug treatment

According to statistics, as of the end of 2020, there are about 175 related drugs under research in the world, of which 35 are currently in clinical phase I research, and 78 are in clinical phase II or phase III research
.

Although the number of declarations is huge, the results are not satisfactory.

3.
Surgical treatment

3.
Surgical treatment

Bariatric surgery may be an effective alternative for behavioral modification and drug-insensitive NASH patients
.

Bariatric surgery is an effective weight loss therapy that has developed rapidly in recent years

New target for potential treatment of NASH achieves breakthrough in China

New targets for potential treatment of NASH achieve breakthroughs in China

On March 12, 2022, Lv Ling's team from Nanjing Medical University published a research paper entitled "Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis" in the well-known journal Journal of Hepatology, and discovered XBP1 inhibitors.
It can be used as a potential new target for the treatment of NASH (Figure 2)
.

Figure 2 Research results (source: [2])

Figure 2 Research results (source: [2]) Figure 2 Research results (source: [2])

In this study, human liver tissues were obtained from NASH patients and controls to evaluate the expression of X-box-binding protein-1 (XBP1).
Except (Xbp1ΔM?), macrophage-specific Nlrp3 knockout and wild-type (Xbp1FL/FL or Nlrp3FL/FL) mice were fed a high-fat diet for 26 weeks or a methionine/choline-deficient diet for 6 weeks
.
The final results of this study show that the expression of XBP1 is significantly up-regulated in liver samples from NASH patients, which can regulate the development of NASH, and XBP1 inhibitors can prevent steatohepatitis, thus serving as a potential target for the treatment of NASH
.

The disadvantages of staying up late are well known, but in today's fast-paced life, few people can avoid staying up late.
Sleeping on weekends to alleviate the harm caused by staying up late is also a solution
.
Based on this study, we understand the importance of weekend sleep supplementation in relieving nonalcoholic fatty liver disease
.
Therefore, in addition to life behavior modification, drug treatment and surgical treatment, the treatment methods for NAFLD will continue to make new progress, bringing new hope to the majority of NAFLD patients
.

Original source:

Original source:

Qi Wang, Haoming Zhou, Qingfa Bu, et al.
Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Journal of Hepatology.
2022 Mar 12.
doi: https://doi.
org/10.
1016/j.
jhep.
2022.
02 .
031.

leave a message here